6 completed. 3 Phase 3, 2 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
| Not applicable | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow phospholamban: new trials by email Literature Review of phospholamban trials Research Report on phospholamban
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2) Extended-Release Naltrexone, Extended Release Buprenorphine, Placebo (PLB) Injectable matched to XR-NTX - Cocaine Use Disorder | Phase 2 | Completed | University of Texas Southwestern Medical Center | 427 | 2023-04-18 | 2025-10-21 |
| Comparison of Active Cycle of Breathing Technique and Pursed Lip Breathing With TheraPep Thera PEP, ACBT and PLB - Chronic Obstructive Pulmonary Disease Exacerbation | Not applicable | Completed | University of Jazan | 40 | 2022-12-30 | 2023-05-19 |
| Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder Naltrexone: Vivitrol®, Placebo (PLB) Injectable, Bupropion: Wellbutrin XL® - Methamphetamine Use Disorder | Phase 3 | Completed | University of Texas Southwestern Medical Center | 403 | 2017-05-05 | 2026-10-27 |
| Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients Chiglitazar, Placebo - Type 2 Diabetes | Phase 3 | Completed | Chipscreen Biosciences, Ltd. | 535 | 2014-06-01 | 2019-10-25 |
| Selenium Supplementation in Pregnancy Selenium, Sugar Pill Placebo, Selenium + L-Thyroxine (LT4) - Pregnancy, Infertility | Not applicable | Completed | University of Roma La Sapienza | 56 | 2012-04-01 | 2018-01-30 |
| An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A GSK 573719 +GW642444 125/25, GSK573719 + GW642444 62.5/25, GSK 573719 125 - Pulmonary Disease, Chronic Obstructive | Phase 3 | Completed | GlaxoSmithKline | 349 | 2011-03-01 | 2017-10-11 |
Pulmonary Disease, Chronic Obstructive (2) · Abortion, Spontaneous (1) · Cocaine-Related Disorders (1) · Diabetes Mellitus, Type 2 (1) · Infertility (1) · Postpartum Thyroiditis (1) · Pre-Eclampsia (1)
University of Texas Southwestern Medical Center (2) · Chipscreen Biosciences, Ltd. (1) · GlaxoSmithKline (1) · University of Jazan (1) · University of Roma La Sapienza (1)
United States (3) · Bulgaria (1) · China (1) · Estonia (1) · Germany (1) · Italy (1) · Russia (1) · Saudi Arabia (1) · United Kingdom (1)
Madhukar Trivedi, MD (2) · Abu Shaphe (1) · Andrea M Isidori, MD, PhD (1) · Linong Ji, Dr. (1)
PMID 33497547, PMID 37245855, PMID 37377462, PMID 38665252, PMID 38856086, PMID 40360074, PMID 40623319, PMID 40767786, PMID 42180350, PMID 42504048
UG1DA020024 (2)